Avecho and Chimeric surge as trial and cash catalysts land; Island extends gains on USAMRIID deal

• Avecho Biotechnology (ASX:AVE) jumped on progress toward interim Phase III data due in June 2026
• Chimeric Therapeutics (ASX:CHM) rallied after securing a $1.785m advance against its FY26 R&D tax incentive
• Island Pharmaceuticals (ASX:ILA) rose on a three-year USAMRIID agreement to speed Marburg drug work
• Little Green Pharma (ASX:LGP) pushed ahead with its Cannatrek scheme, with a 10 April 2026 meeting date set